Our decision to selectively partner our proprietary technology has validated our investment in suprachoroidal delivery using our
SCS Microinjector® and has expanded our overall development pipeline.
We have completed attractive licensing agreements with ideal partners for the commercialization and further development of XIPERE.
Arctic Vision has an exclusive license to develop and commercialize XIPERE for indications associated with uveitis in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea. They also have the right to develop and commercialize XIPERE for additional ophthalmic indications in Greater China and South Korea, with consent from Clearside.
To learn more about our programs and potential business development opportunities, please contact
Rick McElheny, VP, Business Development at email@example.com.